Resumen de IA
Revisamos 10000 resultados en vivo para multi cancer early detection and liquid biopsy y los redujimos a 3 opciones que parecen valer más la pena comparar primero.
Los temas más fuertes en esta lista son Cancer Screening y Genomics.
Revisamos 10000 resultados en vivo para multi cancer early detection and liquid biopsy y los redujimos a 3 opciones que parecen valer más la pena comparar primero.
Los temas más fuertes en esta lista son Cancer Screening y Genomics.
Fuente: The Medical City
Descripción
A liquid biopsy genomic test designed for the early detection of multiple cancer types, offered through a partnership with Gene Solutions at the TMC NGS facility.
Ideal para
Early cancer detection, Liquid biopsy screening, High Risk individuals y Preventive healthcare
Valoración
Fuente: Lucence
Descripción
Proprietary genomic sequencing technology for detecting cancer signals early and guiding therapeutic selection via non-invasive blood tests.
Ideal para
Early cancer screening, Treatment selection, Liquid biopsy diagnostics y Personalized oncology
Valoración
Fuente: National Cancer Centre Singapore (NCCS)
Descripción
The RISE institute at NCCS evaluates and implements Multi-Cancer Early Detection (MCED) tests, which aim to screen for multiple cancer types simultaneously through advanced blood-based technology.
Ideal para
Early cancer detection, Preventative screening, Multi Cancer blood tests y Research participants
Valoración
| Comparar | SPOT-MAS Multi-Cancer Early Detection | Multi-Cancer Early Detection and Liquid Biopsy | RISE Institute Multi-Cancer Early Detection (MCED) Evaluation |
|---|---|---|---|
| Fuente | The Medical City | Lucence | National Cancer Centre Singapore (NCCS) |
| Descripción | A liquid biopsy genomic test designed for the early detection of multiple cancer types, offered through a partnership with Gene Solutions at the TMC NGS facility. | Proprietary genomic sequencing technology for detecting cancer signals early and guiding therapeutic selection via non-invasive blood tests. | The RISE institute at NCCS evaluates and implements Multi-Cancer Early Detection (MCED) tests, which aim to screen for multiple cancer types simultaneously through advanced blood-based technology. |
| Ideal para | Early cancer detection, Liquid biopsy screening, High Risk individuals y Preventive healthcare | Early cancer screening, Treatment selection, Liquid biopsy diagnostics y Personalized oncology | Early cancer detection, Preventative screening, Multi Cancer blood tests y Research participants |
| Acción | |||
| Valoración |
Si quieres empezar con la opción más equilibrada, te recomiendo:
"SPOT-MAS Multi-Cancer Early Detection de The Medical City."
Lo elegí porque TMC combines world-class clinical care with advanced genomic screening for early cancer detection in a hospital-based setting.